Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

ABSTRACT:

Background

Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population.

Methods

We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group). Treatment was to continue until the occurrence of disease progression or unacceptable side effects. The primary end point was progression-free survival.

Results

At a median fo

SUBMITTER: Facon T 

PROVIDER: S-EPMC10045721 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature